{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2009"],"condition":["Metastatic Colorectal Cancer","Cáncer colorrectal metastásico no pretratado","Colorectal Neoplasms","Colorectal cancer NOS"],"disease":["Metastatic Colorectal Cancer","Cáncer Colorrectal Metastásico No Pretratado","Colorectal Neoplasms","Colorectal Cancer Nos"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2070371"],"location":["Spain"],"study_start_month":["4"],"keyword":["Irinotecan","Xeloda 150mg.","Avastin 400mg.","Capecitabine","Xeloda 500mg.","Avastin 100mg.","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients","description":"The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.","dates":{"creation":"2009-04-15"},"accession":"2070371","cross_references":{"ClinicalTrials___gov":["NCT00875771"],"EU Clinical Trials Register":["2008-004688-20"]}}